| Symbol | JAGX |
|---|---|
| Name | JAGUAR HEALTH, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 200 PINE STREET,SUITE 400, SAN FRANCISCO, California, 94104, United States |
| Telephone | +1 415 371-8300 |
| Fax | — |
| — | |
| Website | http://www.jaguar.health |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001585608 |
| Description | Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. Additional info from NASDAQ: |
New Form NT 10-Q - Jaguar Health, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001193125-26-352657 <b>Size:</b> 26 KB
Read moreJaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1
Read moreJaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog
Read moreNew Form 424B3 - Jaguar Health, Inc. <b>Filed:</b> 2026-07-27 <b>AccNo:</b> 0001193125-26-316920 <b>Size:</b> 281 KB
Read moreNew Form 424B3 - Jaguar Health, Inc. <b>Filed:</b> 2026-07-27 <b>AccNo:</b> 0001193125-26-316918 <b>Size:</b> 358 KB
Read moreNew Form EFFECT - Jaguar Health, Inc. <b>Filed:</b> 2026-07-24 <b>AccNo:</b> 9999999995-26-002446 <b>Size:</b> 1 KB
Read moreNew Form EFFECT - Jaguar Health, Inc. <b>Filed:</b> 2026-07-24 <b>AccNo:</b> 9999999995-26-002447 <b>Size:</b> 1 KB
Read moreNew Form PRE 14A - Jaguar Health, Inc. <b>Filed:</b> 2026-07-24 <b>AccNo:</b> 0001193125-26-316119 <b>Size:</b> 1 MB
Read moreNew Form S-1/A - Jaguar Health, Inc. <b>Filed:</b> 2026-07-24 <b>AccNo:</b> 0001193125-26-315711 <b>Size:</b> 801 KB
Read moreAdditional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID)
Read more